Shenyang, ZF • 86-24-2469-6033 • www.lnnk.com
IPO Date: 12/9/09
Exchange and Ticker: Nasdaq: NKBP
Filing Range: 4.53M American Depository Shares @ $10.00 to $12.00
Offering Price: $9.00 per ADS (each ADS was equal to 8 ordinary shares in the IPO)
Close on First Day: $8.67
Offering Size: $45M
Shares Outstanding: 157,460,142M
Underwriters: Jefferies & Co. Inc.
Co-manager: Oppenheimer & Co. Inc.
Company Counsel: Latham & Watkins
Manager Counsel: Shearman & Sterling LLP
Auditor: Ernst & Young LLP
Market Capitalization on 12/31/09: $167.1M
Closing price on 12/31/09: $7.85
China Nuokang Bio-Pharmaceutical operates as a bio-pharmaceutical company. The company focuses on research and development, manufacturing and marketing of hematological and cardiovascular pharmaceutical products. Its products include hemocoagulase and cardiovascular stress imaging agents.
HBM BioVentures AG (via HBM BioVentures II) and Sequoia Capital (via Sequoia Capital China Growth Fund LP)
STOCK HOLDINGS OF VC FUNDS
(For company directors or owners of 5% or more of the company’s shares.)
Owner_No. of shares (as of 12/9/09)_ Value (as of 12/31/09)_Percentage ownership after offering
*Share values were calculated by VCJ based on conversion rate of 8 ordinary shares per ADS, which values 1 ordinary share at $0.98 at the 12/31/09 closing price of $7.85 per ADS. See China Nuokang proxy statement filed with SEC on 12/10/09.
**Shares are held by HBM BioMed China, which is wholly owned by HBM BioVentures. HBM held 5.69M shares prior to the IPO, but sold 2.84M shares as part of the IPO.
Year_No. of investors_Round Amount $M_Valuation $M
12/20/07 _ 2_$17.00_n/a
Total Revenue: 121,661,000 RMB_147,875,000 RMB_225,399,000 RMB
Net Income: 26,304,000 RMB_35,195,000 RMB_63,620,000 RMB
EPS: 0.26 RMB_0.05 RMB_0.43 RMB
*Company’s financials are listed in RMB, or Chinese yuan, per the company’s proxy statement. 1 RMB was equal to $0.146 on 1/13/09, according to the Google Currency Converter.
Sources: Thomson Reuters and China Nuokang proxy statement filed with SEC on 12/9/09.